Schwinger R H, Böhm M, Erdmann E
Medical Clinic I, Grosshadern Hospital, Universität München, Germany.
Am J Hypertens. 1991 Feb;4(2 Pt 2):185S-187S. doi: 10.1093/ajh/4.2.185s.
The use of calcium antagonists in the treatment of cardiac failure is limited by the negative inotropic effects they exert. The comparative inotropic activity of four calcium antagonists was therefore investigated, using electrically driven human papillary muscle strips and human atrial trabeculae. These inotropic effects were studied with cumulative concentration-response curves. The four calcium antagonists included in this study were all found to significantly (P less than or equal to .05) diminish the force of contraction above 0.01 mumol/L, but with different potencies. On the basis of the relationship between therapeutic vasoactive plasma concentrations and the negative inotropic effective concentrations in our system in vitro, the ranking order of potential negative inotropism in the treatment of cardiac failure with calcium antagonists was verapamil greater than nifedipine greater than diltiazem greater than isradipine. Thus, to minimize cardiodepressant risk, the use of calcium antagonists with weak negative inotropic effects at relevant concentrations should be preferred, especially in the case of patients with compromised cardiac function.
钙拮抗剂在心力衰竭治疗中的应用因具有负性肌力作用而受到限制。因此,利用电驱动的人乳头肌条和人心房小梁,对四种钙拮抗剂的相对肌力活性进行了研究。采用累积浓度 - 反应曲线对这些肌力作用进行了研究。本研究中包含的四种钙拮抗剂均被发现,在浓度高于0.01 μmol/L时均能显著(P≤0.05)降低收缩力,但效价不同。根据我们体外系统中治疗性血管活性血浆浓度与负性肌力有效浓度之间的关系,钙拮抗剂在心力衰竭治疗中潜在负性肌力作用的排序为维拉帕米>硝苯地平>地尔硫䓬>伊拉地平。因此,为将心脏抑制风险降至最低,应优先使用在相关浓度下具有较弱负性肌力作用的钙拮抗剂,尤其是对于心功能受损的患者。